Adding to targeted oncology portfolio, Zai gains China rights to Turning Point’s repotrectinib

In its latest cross-border in-licensing deal, Zai gained territorial rights to yet another targeted cancer therapy via a deal with Turning Point for repotrectinib, which is in a pivotal trial that could lead to approvals in both lung cancer and a tissue-agnostic indication.

Zai Lab Ltd. (NASDAQ:ZLAB) will pay $25 million up front to gain rights in Greater China to repotrectinib, a small molecule inhibitor of ALK, ROS1, TrkA, TrkB and TrkC. Turning Point Therapeutics Inc. (NASDAQ:TPTX) expects data this year from 30-40 patients in the Phase I/II TRIDENT-1 trial, which includes pivotal cohorts in ROS1-positive non-small cell lung cancer (NSCLC) and NTRK-positive solid tumors...